false
OasisLMS
Catalog
ORN Webinar Fall 2021 #3 - COVID 19 Changes to Met ...
Event Recording
Event Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video discussed changes to methadone treatment at an opioid treatment program in Central Pennsylvania during the COVID-19 pandemic. Dr. Sarah Kawasaki, MD, presented the information and discussed the history of methadone treatment in the country, including the regulations and stigma associated with it. She also discussed the impact of COVID-19 on the clinic's policies and the outcomes for patients during that time. The clinic made changes to its take-home medication policies to reduce exposure to COVID-19, and this resulted in a significant decrease in attrition rates. However, the state of Pennsylvania plans to return to pre-pandemic regulations, which has led to disappointment among patients and providers. Dr. Kawasaki discussed the need for new legislation to improve the regulations and reduce stigma surrounding opioid treatment programs. The video also addressed questions about the use of THC for patients, telehealth services during the pandemic, and the handling of UDS with telehealth. Additionally, the dosage ranges for methadone maintenance were discussed, as well as the policy for patients who are non-compliant. The video concluded with a discussion on the future advocacy for better regulations and outcomes in opioid treatment programs.
Keywords
methadone treatment
opioid treatment program
COVID-19 pandemic
regulations
stigma
take-home medication policies
attrition rates
legislation
telehealth services
×
Please select your language
1
English